Acute erythroleukemia, M6b

Archives of Pathology and Laboratory Medicine

Volumn 124, Issue 2, 2000, Pages 330-331

  Mazzella, Fermina M ^a   Schumacher, Harold R ^b  

^a GUTHRIE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; CYTOGENETICS; ERYTHROLEUKEMIA; HUMAN; HUMAN TISSUE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYTARABINE; CYTOGENETICS; DAUNORUBICIN; FATAL OUTCOME; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS;

EID: 0033966419     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Kowal-Vern A, Cotelingam J, Schumacher HR. The prognostic significance of proerythroblasts in acute erythroleukemia. Am J Clin Pathol. 1992;98:34-40.
2. Mazzella FM, Kowal-Vern A, Shrit MA, et al. Acute erythroleukemia: evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics and prognosis. Am J Clin Pathol. 1998;110:590-598.
3. Mazzella FM, Tolbert D, Kowal-Vern A, et al. p53 gene mutation in acute erythroleukemia: differences among subtypes M6a, M6b and M6c. Lab Hematol. 1999;5:28-36.
4. Schumacher HR. Case 15. In: Acute Leukemia: Approach to Diagnosis. New York, NY: Igaku-Shoin; 1990:225-232.
5. Society for Hematopathology Program. Proposed World Health Organisation classification of neoplastic diseases of hematopoietic and lymphoid tissues. Am J Surg Pathol. 1997;21:114-121.